Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 20(24)2019 Dec 11.
Article in English | MEDLINE | ID: mdl-31835809

ABSTRACT

Farber disease is a rare lysosomal storage disorder resulting from acid ceramidase deficiency and subsequent ceramide accumulation. No treatments for Farber disease are clinically available, and affected patients have a severely shortened lifespan. We have recently reported a novel acid ceramidase deficiency model that mirrors the human disease closely. Acid sphingomyelinase is the enzyme that generates ceramide upstream of acid ceramidase in the lysosomes. Using our acid ceramidase deficiency model, we tested if acid sphingomyelinase could be a potential novel therapeutic target for the treatment of Farber disease. A number of functional acid sphingomyelinase inhibitors are clinically available and have been used for decades to treat major depression. Using these as a therapeutic for Farber disease, thus, has the potential to improve central nervous symptoms of the disease as well, something all other treatment options for Farber disease can't achieve so far. As a proof-of-concept study, we first cross-bred acid ceramidase deficient mice with acid sphingomyelinase deficient mice in order to prevent ceramide accumulation. Double-deficient mice had reduced ceramide accumulation, fewer disease manifestations, and prolonged survival. We next targeted acid sphingomyelinase pharmacologically, to test if these findings would translate to a setting with clinical applicability. Surprisingly, the treatment of acid ceramidase deficient mice with the acid sphingomyelinase inhibitor amitriptyline was toxic to acid ceramidase deficient mice and killed them within a few days of treatment. In conclusion, our study provides the first proof-of-concept that acid sphingomyelinase could be a potential new therapeutic target for Farber disease to reduce disease manifestations and prolong survival. However, we also identified previously unknown toxicity of the functional acid sphingomyelinase inhibitor amitriptyline in the context of Farber disease, strongly cautioning against the use of this substance class for Farber disease patients.


Subject(s)
Farber Lipogranulomatosis/enzymology , Sphingomyelin Phosphodiesterase/deficiency , Acid Ceramidase/metabolism , Amitriptyline/pharmacology , Animals , Ceramides/metabolism , Cytokines/metabolism , Farber Lipogranulomatosis/pathology , Mice, Inbred C57BL , Sphingomyelin Phosphodiesterase/metabolism , Survival Analysis , Weight Gain/drug effects
2.
Am J Pathol ; 189(2): 320-338, 2019 02.
Article in English | MEDLINE | ID: mdl-30472209

ABSTRACT

Farber disease (FD) is a debilitating lysosomal storage disorder characterized by severe inflammation and neurodegeneration. FD is caused by mutations in the ASAH1 gene, resulting in deficient acid ceramidase (ACDase) activity. Patients with ACDase deficiency exhibit a broad clinical spectrum. In classic cases, patients develop hepatosplenomegaly, nervous system involvement, and childhood mortality. Ocular manifestations include decreased vision, a grayish appearance to the retina with a cherry red spot, and nystagmus. That said, the full effect of ACDase deficiency on the visual system has not been studied in detail. We previously developed a mouse model that is orthologous for a known patient mutation in Asah1 that recapitulates human FD. Herein, we report evidence of a severe ocular pathology in Asah1P361R/P361R mice. Asah1P361R/P361R mice exhibit progressive retinal and optic nerve pathology. Through noninvasive ocular imaging and histopathological analyses of these Asah1P361R/P361R animals, we revealed progressive inflammation, the presence of retinal dysplasia, and significant storage pathology in various cell types in both the retina and optic nerves. Lipidomic analyses of retinal tissues revealed an abnormal accumulation of ceramides and other sphingolipids. Electroretinograms and behavioral tests showed decreased retinal and visual responses. Taken together, these data suggest that ACDase deficiency leads to sphingolipid imbalance, inflammation, dysmorphic retinal and optic nerve pathology, and severe visual impairment.


Subject(s)
Acid Ceramidase/genetics , Farber Lipogranulomatosis , Mutation, Missense , Optic Nerve , Retina , Vision Disorders , Acid Ceramidase/metabolism , Amino Acid Substitution , Animals , Ceramides/genetics , Ceramides/metabolism , Disease Models, Animal , Farber Lipogranulomatosis/enzymology , Farber Lipogranulomatosis/genetics , Farber Lipogranulomatosis/pathology , Inflammation/enzymology , Inflammation/genetics , Inflammation/pathology , Mice , Mice, Mutant Strains , Optic Nerve/enzymology , Optic Nerve/pathology , Retina/enzymology , Retina/pathology , Sphingolipids/genetics , Sphingolipids/metabolism , Vision Disorders/enzymology , Vision Disorders/genetics , Vision Disorders/pathology
3.
Nat Commun ; 9(1): 1621, 2018 04 24.
Article in English | MEDLINE | ID: mdl-29692406

ABSTRACT

Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine, the backbone of all sphingolipids, to regulate many cellular processes. Abnormal function of aCDase leads to Farber disease, spinal muscular atrophy with progressive myoclonic epilepsy, and is associated with Alzheimer's, diabetes, and cancer. Here, we present crystal structures of mammalian aCDases in both proenzyme and autocleaved forms. In the proenzyme, the catalytic center is buried and protected from solvent. Autocleavage triggers a conformational change exposing a hydrophobic channel leading to the active site. Substrate modeling suggests distinct catalytic mechanisms for substrate hydrolysis versus autocleavage. A hydrophobic surface surrounding the substrate binding channel appears to be a site of membrane attachment where the enzyme accepts substrates facilitated by the accessory protein, saposin-D. Structural mapping of disease mutations reveals that most would destabilize the protein fold. These results will inform the rational design of aCDase inhibitors and recombinant aCDase for disease therapeutics.


Subject(s)
Acid Ceramidase/chemistry , Acid Ceramidase/metabolism , Farber Lipogranulomatosis/enzymology , Muscular Atrophy, Spinal/enzymology , Acid Ceramidase/genetics , Binding Sites , Biocatalysis , Ceramides/chemistry , Ceramides/metabolism , Enzyme Activation , Farber Lipogranulomatosis/genetics , Humans , Hydrophobic and Hydrophilic Interactions , Muscular Atrophy, Spinal/genetics , Mutation , Protein Folding , Saposins/genetics , Saposins/metabolism , Sphingolipids/chemistry , Sphingolipids/metabolism
4.
Adv Biol Regul ; 63: 122-131, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27771292

ABSTRACT

Over the past three decades, extensive research has been able to determine the biologic functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989). These studies have managed to define the metabolism, regulation, and function of these bioactive sphingolipids. This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis. Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids. Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 (ACER2), and alkaline ceramidase 3 (ACER3). These ceramidases are classified according to their optimal pH for catalytic activity. AC, which is localized to the lysosomal compartment, has been associated with Farber's disease and is involved in the regulation of cell viability. Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis. ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation. ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage. ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-associated Purkinje cell degeneration. This review seeks to consolidate the current knowledge regarding these key cellular players.


Subject(s)
Acid Ceramidase/metabolism , Alkaline Ceramidase/metabolism , Neutral Ceramidase/metabolism , Sphingolipids/metabolism , Acid Ceramidase/genetics , Alkaline Ceramidase/genetics , Animals , Farber Lipogranulomatosis/enzymology , Farber Lipogranulomatosis/genetics , Farber Lipogranulomatosis/pathology , Gene Expression , Humans , Hydrogen-Ion Concentration , Inflammation , Kinetics , Neoplasms/enzymology , Neoplasms/genetics , Neoplasms/pathology , Neurodegenerative Diseases/enzymology , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/pathology , Neutral Ceramidase/genetics , Signal Transduction , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...